Lineage Cell Therapeutics IncEigentümerstruktur
| Preis (2026-07-30) | 52W Hoch | 52W Tief |
| 1.11 USD | 2,09 USD | 0,946 USD |
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 5,5 USD | 4 | 2 | 1 | 0 | 0 |
| #Shares | Short [%] | Short Ratio |
| 249.298.295 | 20,06 | 14,34 |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name Lineage Cell Therapeutics Inc
Mitarbeiter 72
Handelsplatz AMEX
Ticker Symbol LCTX
IPO Datum 1992-03-06
Adresse 2173 Salk Avenue, Carlsbad, CA, United States, 92008
Webseite https://www.lineagecell.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Mr. Brian M. Culley M.A., M.B.A. | CEO, President & Director |
| 2 | Ms. Jill Ann Howe | Chief Financial Officer |
| 3 | Mr. George A. Samuel III, J.D. | General Counsel & Company Secretary |
| 4 | Ms. Ioana C. Hone | Director of Investor Relations |
| 5 | Dr. Charlotte Hubbert Ph.D. | Vice President of Corporate Strategy & Development |
| 6 | Dr. Priyantha Herath M.D., Ph.D. | Senior VP & Head of Clinical Operations |
| 7 | Dr. Rami Skaliter M.Sc., Ph.D. | Chief Executive Officer of Cell Cure Neurosciences |
| 8 | Ms. Alexandra Hernandez | Senior Director of Finance & Controller |
| 9 | Dr. Harold D. Waitz Ph.D. | Vice President of Regulatory Affairs & Quality Control |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
Für dieses Unternehmen liegen derzeit keine Daten zu institutionellen Investoren vor.